Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy-Reference-Cited by-同舟云学术

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Published:2016-04-28 Issue:10 Volume:114 Page:1084-1089
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bowyer S,Prithviraj P,Lorigan P,Larkin J,McArthur G,Atkinson V,Millward M,Khou M,Diem S,Ramanujam S,Kong B,Liniker E,Guminski A,Parente P,Andrews M C,Parakh S,Cebon J,Long G V,Carlino M S,Klein O

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016107.pdf

Reference27 articles.

1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 (19): 3167–3175.

2. Bristol-Myer Squibb (2013) Investigator Brochure NIVOLUMAB BMS-936558 MDX1106 Version 12.

3. Danlos FX, Pagès C, Roux J, Jebali M, Gornet JM, Bagot M, Lebbé C (2015) Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res 25: 178–179.

4. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194: 950–959.

5. Daud A, Ribas A, Robert C, Hodi S, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, Li XN, Ebbinghaus S, Kang SP, Hamid O (2015) Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33 (Suppl): ): abstr 9005.

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling major histocompatibility complex-mediated pan-cancer immune features by integrated single-cell and bulk RNA sequencing;Cancer Letters;2024-08

2. Predicting the likelihood of elevated transaminases in lung cancer patients undergoing immune checkpoint blockade;2024-05-12

3. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23

4. Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer;Frontiers in Microbiology;2024-01-24

5. Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress;European Journal of Pharmacology;2023-12